title: The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling.
abstract: Dysregulated WNT/β-catenin signaling in murine testes results in a phenotype with complete germ cell loss that resembles human Sertoli cell-only syndrome. In other systems, including the ovary, dysregulated WNT/β-catenin induces tumorigenesis but no tumors are observed in the mutant testes without deletion of a tumor suppressor, such as phosphatase and tensin homolog (PTEN). Müllerian inhibiting substance (MIS, also known as AMH), a member of the transforming growth factor-β family of growth factors responsible for Müllerian duct regression in fetal males, has been shown to inhibit tumor growth in vitro and in vivo but its role as an endogenous tumor suppressor has never been reported. We have deleted the MIS type 2 receptor (MISR2), and thus MIS signaling, in mice with dysregulated WNT/β-catenin and show that these mice develop testicular stromal tumors with 100% penetrance within a few months postnatal. The tumors are highly proliferative and have characteristics of either Sertoli cell tumors or progenitor Leydig cell tumors based on their marker profiles and histology. Phosphorylated Sma and mothers against decapentaplegic-related homolog 1/5/8 is absent in the tumors and β-catenin target genes are induced. The tumor suppressor TP53 is also highly expressed in the tumors, as is phosphorylated γH2AX, which is indicative of DNA damage. The phenotype of these tumors closely resembles those observed when PTEN is also deleted in mice with dysregulated WNT/β-catenin. Tumorigenesis in these mice provides conclusive evidence that physiological MIS signaling is a tumor suppressor mechanism and suggests that targeted treatment of MISR2-expressing cancers with therapeutic MIS should have a beneficial effect on tumor progression.
authors.affiliation: Vincent Center for Reproductive Biology, Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Pradeep S
authors.initials: PS
authors.lastname: Tanwar
authors.forename: Arno E
authors.initials: AE
authors.lastname: Commandeur
authors.forename: LiHua
authors.initials: L
authors.lastname: Zhang
authors.forename: Makoto M
authors.initials: MM
authors.lastname: Taketo
authors.forename: Jose M
authors.initials: JM
authors.lastname: Teixeira
mesh_terms: D000818:Animals; D043171:Chromosomal Instability; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018000:Receptors, Peptide / Q000032:analysis / Q000502:physiology*; D018125:Receptors, Transforming Growth Factor beta / Q000032:analysis / Q000502:physiology*; D055758:SOX9 Transcription Factor / Q000032:analysis; D018312:Sex Cord-Gonadal Stromal Tumors / Q000209:etiology; D015398:Signal Transduction / Q000502:physiology*; D013736:Testicular Neoplasms / Q000209:etiology / Q000517:prevention & control*; D025521:Tumor Suppressor Proteins / Q000502:physiology*; D060449:Wnt Signaling Pathway / Q000502:physiology; D051176:beta Catenin / Q000502:physiology*
chemical_list: C495267:CTNNB1 protein, mouse; D018000:Receptors, Peptide; D018125:Receptors, Transforming Growth Factor beta; D055758:SOX9 Transcription Factor; C527933:Sox9 protein, mouse; D025521:Tumor Suppressor Proteins; C084621:anti-Mullerian hormone receptor; D051176:beta Catenin